ABBVIE INC. (ABBV) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 20...
ABBVIE INC.'s revenue increased 8.6% year over year, from $56.33B to $61.16B.
Net income decreased 1.2% over the same period, from $4.28B to $4.23B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 139% in total.
Total debt decreased by 8.5% to $61.44B.
Operating cash flow grew 1.2% to $19.03B.
ABBVIE INC. maintains a moderate net profit margin of 6.9%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $40.02B+53.4% | $4.04B | $25.31B | $9.56B | $18.09B | $136.22B | $55.63B | $12.09B |
| Q1 FY2024 | $12.31B-69.2% | $1.37B | $8.22B | $2.80B | $4.04B | $148.87B | $63.81B | $8.01B |
| Q2 FY2024 | $26.77B+117.5% | $2.74B | $18.48B | $6.80B | $6.31B | $141.94B | $70.63B | $6.78B |
| Q3 FY2024 | $41.23B+54.0% | $4.30B | $28.72B | $10.63B | $11.76B | $143.42B | $71.08B | $6.03B |
| Q1 FY2025 | $13.34B-67.6% | $1.29B | $9.34B | $3.73B | $1.64B | $136.16B | $66.12B | $1.42B |
| Q2 FY2025 | $28.77B+115.6% | $2.22B | $20.42B | $8.63B | $6.79B | $137.18B | $68.52B | $-183.0M |
| Q3 FY2025 | $44.54B+54.8% | $2.41B | $30.89B | $10.53B | $13.81B | $133.90B | $66.76B | $-2.64B |
| Q1 FY2026 | $15.00B-66.3% | $695.0M | $10.78B | $3.99B | $3.83B | $136.46B | $64.53B | $-6.66B |
Balance Sheet Summary (Latest Period)
Total Assets
$133.96B
Total Liabilities
$137.23B
Total Equity
$-3.27B
Cash & Equivalents
$5.26B
Total Debt
$61.44B
Current Assets
$29.06B
Current Liabilities
$43.29B
Retained Earnings
$-15.49B